Rua Bioscience Limited Stocks

NZ$ 0.03Last Updated 07.11.2025

Issuer Rating

2/7

Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

NZ$ 3.76M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NZ$ 0.03
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Rua Bioscience Limited engages in the research, development, and manufacturing of pharmaceutical products in New Zealand and internationally. It offers cannabinoid derived medicines. The company was formerly known as Hikurangi Cannabis Company Limited and changed its name to Rua Bioscience Limited in October 2019. Rua Bioscience Limited was founded in 2016 and is based in...

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks